VS-6766 Market Size, Forecast, and Emerging Insight - 2032
상품코드:1462319
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
Verastem Oncology가 개발한 VS-6766은 RAF/MEK 클램프이며, MEK와 ARAF, BRAF, CRAF의 불활성 복합체를 유도하고 RAS 경로를 최대로 억제하여 보다 완전하고 지속적인 항종양 효과를 창출할 수 있습니다. 6766은 하나의 분자로 RAF와 MEK를 모두 억제하므로 저항성을 극복하고 궁극적으로 종양 성장과 증식을 억제하는 데 도움이 될 수 있으며, MEK의 RAF 인산화를 억제함으로써 VS-6766은 pMEK를 유도하지 않는 장점이 있습니다. 예비 연구에 따르면 VS-6766은 치료 활성을 향상시킬 수 있으며, VS-6766을 단독으로 사용하면 난치성 부인과 암에서 RAS 경로의 돌연변이를 횡단하는 것으로 예비 데이터에 따르면 VS-6766은 난치성 부인과 암에서 RAS 경로의 돌연변이를 나타냅니다.
VS-6766은 새로운 간헐적 투여 스케줄과 간편한 경구용 요법을 통해 현재 사용 가능한 MEK 단독 억제제보다 더 나은 내약성을 제공할 수 있으며, VS-6766은 여러 표적 계열의 약물과의 병용요법에서 최적의 파트너가 될 수 있습니다. 더 나은 결과를 가져올 수 있을 것으로 기대됩니다.
앞으로 몇 년동안 난소암 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 난소암 치료/개선에 대한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, VS-6766의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, 난소암을 대상으로 하는 다른 신흥 제품들이 VS-6766과 치열한 시장 경쟁을 벌일 것으로 예상되고 있습니다. 향후 후발 신약이 출시될 경우 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 난소암 치료제 VS-6766 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.
목차
제1장 보고서 서론
제2장 난소암 치료제 VS-6766 개요
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신흥 치료법)
제5장 VS-6766 시장 평가
난소암 치료제 VS-6766 시장 전망
주요 7개국 분석
주요 7개국의 난소암 치료제 VS-6766 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight에 대해
제12장 보고서 구입 옵션
LSH
영문 목차
영문목차
"VS-6766 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VS-6766 for ovarian cancer in the seven major markets. A detailed picture of the VS-6766 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VS-6766 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VS-6766 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
Drug Summary:
VS-6766, developed by Verastem Oncology, is an RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially creating a more complete and durable antitumor response through maximal RAS pathway inhibition. VS-6766 blocks both RAF and MEK in a single molecule, suggesting it may help overcome resistance and ultimately block tumor growth and proliferation. By inhibiting RAF phosphorylation of MEK, VS-6766 has the advantage of not inducing pMEK, and by inhibiting ERK signaling more completely, preliminary research indicates VS-6766 may confer enhanced therapeutic activity. When used alone, preliminary data show that VS-6766 demonstrates across RAS pathway mutations in refractory gynecologic cancers.
VS-6766 offers a novel intermittent dosing schedule and convenient oral regimen with the possibility of better tolerability than currently available MEK-only inhibitors, which makes VS-6766 an optimal partner for combination therapy with agents from multiple target classes that may deliver better patient outcomes where they are needed most.
Scope of the Report:
The report provides insights into:
A comprehensive product overview including the VS-6766 description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
Elaborated details on VS-6766 regulatory milestones and other development activities have been provided in this report.
The report also highlights the VS-6766 research and development activities in ovarian cancer across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around VS-6766.
The report contains forecasted sales of VS-6766 for ovarian cancer till 2032.
Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
The report also features the SWOT analysis with analyst views for VS-6766 in ovarian cancer.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VS-6766 Analytical Perspective by DelveInsight
In-depth VS-6766 Market Assessment
This report provides a detailed market assessment of VS-6766 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
VS-6766 Clinical Assessment
The report provides the clinical trials information of VS-6766 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VS-6766 dominance.
Other emerging products for ovarian cancer are expected to give tough market competition to VS-6766 and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VS-6766 in ovarian cancer.
Our in-depth analysis of the forecasted sales data of VS-6766 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VS-6766 in ovarian cancer.
Key Questions:
What is the product type, route of administration and mechanism of action of VS-6766?
What is the clinical trial status of the study related to VS-6766 in ovarian cancer and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VS-6766 development?
What are the key designations that have been granted to VS-6766 for ovarian cancer?
What is the forecasted market scenario of VS-6766 for ovarian cancer?
What are the forecasted sales of VS-6766 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how are these giving competition to VS-6766 for ovarian cancer?
Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?
